keyword
MENU ▼
Read by QxMD icon Read
search

Olmesartan

keyword
https://www.readbyqxmd.com/read/28904053/cardiovascular-biomarkers-in-hypertensive-patients-with-medical-treatment-results-from-the-randomized-teamsta-protect-i-trial
#1
Annika Jagodzinski, Johannes Tobias Neumann, Francisco Ojeda, Nils Arne Sörensen, Philipp Wild, Thomas Münzel, Tanja Zeller, Dirk Westermann, Stefan Blankenberg
BACKGROUND: High blood pressure (BP) is associated with an increased rate of cardiovascular events and mortality. Cardiovascular biomarkers are able to predict long-term risk in the general population, particularly in diseased cohorts. We undertook an investigation of the effect of 2 different antihypertensive treatments on cardiovascular biomarkers in a randomized trial. METHODS: The TEAMSTA study included 481 hypertensive patients. They were randomized to either 80-mg telmisartan + 5-mg amlodipine (TA) or 40-mg olmesartan + 12...
September 13, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28871467/epigallocatechin-gallate-protects-against-homocysteine-induced-vascular-smooth-muscle-cell-proliferation
#2
Xiao Li Zhan, Xiu Hong Yang, Yan Hong Gu, Li Li Guo, Hui Min Jin
Epigallocatechin gallate (EGCG), a bioactive ingredient of green tea, plays a protective role in the cardiovascular system. Homocysteine (Hcy) is a major risk factor for chronic kidney disease and cardiovascular disease. The present study aimed to investigate the role of EGCG in Hcy-induced proliferation of vascular smooth muscle cells (VSMCs) and its underlying mechanism. We also explored the roles of rennin-angiotensin system (RAS), extracellular signal-regulated kinases (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK) in this process...
September 4, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28868495/sprue-like-enteropathy-associated-with-olmesartan-an-unrecognized-emerging-drug-induced-enteropathy
#3
Luís Carvalho Lourenço, Joana Carvalho E Branco, Liliana Santos, Alexandra Martins, Jorge Reis
No abstract text is available yet for this article.
November 2016: GE Port J Gastroenterol
https://www.readbyqxmd.com/read/28828980/single-pill-triple-fixed-dose-combination-therapy-with-single-component-drug-monitoring-in-treatment-resistant-hypertension-a-pilot-study
#4
Reinhold Kreutz, Jurgen Scholze, Antonios Douros
BACKGROUND: Single-pill fixed dose combination (FDC) therapies are widely used in the treatment of arterial hypertension. OBJECTIVE: This pilot study aimed to evaluate the effects of a FDC therapy combined with therapeutic drug monitoring (TDM) on blood pressure (BP) in patients with treatment resistant hypertension. METHOD: The study population included patients with suspected treatment-resistant hypertension during treatment with at least 3 antihypertensive drugs...
August 21, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28814846/erratum-olmesartan-vs-ramipril-in-the-treatment-of-hypertension-and-associated-clinical-conditions-in-the-elderly-a-reanalysis-of-two-large-double-blind-randomized-studies-at-the-light-of-the-most-recent-blood-pressure-targets-recommended-by-guidelines-corrigendum
#5
https://www.readbyqxmd.com/read/28793821/the-effects-of-lcz696-in-patients-with-hypertension-compared-with-angiotensin-receptor-blockers-a-meta-analysis-of-randomized-controlled-trials
#6
Yang Zhao, Heng Yu, Xu Zhao, Ruixin Ma, Ningyin Li, Jing Yu
LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, has been demonstrated to have greater advantages in the treatment of heart failure compared with angiotensin-converting enzyme inhibitors, enalapril, or angiotensin receptor blockers (ARBs). However, studies that compared the efficacy and safety of LCZ696 against valsartan in patients with hypertension are limited. To provide further evidence for the benefits of LCZ696 and to make this assessment, a meta-analysis of randomized controlled trials (RCTs) was performed...
September 2017: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28706558/qiliqiangxin-enhances-cardiac-glucose-metabolism-and-improves-diastolic-function-in-spontaneously-hypertensive-rats
#7
Jingfeng Wang, Zhiming Li, Yanyan Wang, Jingjing Zhang, Weipeng Zhao, Mingqiang Fu, Xueting Han, Jingmin Zhou, Junbo Ge
Cardiac diastolic dysfunction has emerged as a growing type of heart failure. The present study aims to explore whether Qiliqiangxin (QL) can benefit cardiac diastolic function in spontaneously hypertensive rat (SHR) through enhancement of cardiac glucose metabolism. Fifteen 12-month-old male SHRs were randomly divided into QL-treated, olmesartan-treated, and saline-treated groups. Age-matched WKY rats served as normal controls. Echocardiography and histological analysis were performed. Myocardial glucose uptake was determined by (18)F-FDG using small-animal PET imaging...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/28695464/improving-adherence-to-treatment-and-reducing-economic-costs-of-hypertension-the-role-of-olmesartan-based-treatment
#8
Francesco Vittorio Costa
Poor adherence to antihypertensive treatment is the single most important factor of unsatisfactory blood pressure (BP) control. This review focuses on therapy-related factors affecting adherence and suggests how to improve it with a wise choice of treatment schedule. Complex drug treatment schemes, poor tolerability and drug substitutions are frequent causes of poor adherence which, in turn, causes insufficient BP control, greater incidence of cardiovascular events and, finally, higher global health costs...
July 10, 2017: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://www.readbyqxmd.com/read/28681550/comparison-of-long-term-safety-of-fixed-dose-combinations-azilsartan-medoxomil-chlorthalidone-vs-olmesartan-medoxomil-hydrochlorothiazide
#9
Joel M Neutel, William C Cushman, Eric Lloyd, Bruce Barger, Alison Handley
This 52-week, randomized, open-label study evaluated long-term safety/tolerability of fixed-dose combination azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs fixed-dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with essential hypertension (stage 2; clinic systolic blood pressure 160-190 mm Hg). Initial AZL-M/CLD 40/12.5 mg/d (n=418) or OLM/HCTZ 20/12.5 mg/d (n=419) could be uptitrated during weeks 4 to 52 (AZL-M/CLD to 80/25 mg; OLM/HCTZ to 40/25 mg [United States] or 20/25 mg [Europe]) to meet blood pressure targets...
July 6, 2017: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/28680344/adma-sdma-and-l-arginine-may-be-novel-targets-in-pharmacotherapy-for-complications-due-to-cardiopulmonary-bypass
#10
Aydın Kahraman, Emre Mutlu, Mustafa Aldağ
BACKGROUND: In this study, the effects of olmesartan therapy on asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), L-arginine and inducible nitric oxide synthase (iNOS) levels were investigated in patients undergoing cardiopulmonary bypass. METHODS: Patients were randomly allocated to two groups, control and olmesartan. Olmesartan was administered 30 mg once a day beginning from preoperative day 5 to postoperative day 28 and on operation day...
January 2017: Journal of Medical Biochemistry
https://www.readbyqxmd.com/read/28676728/-olmesartan-associated-enteropathy-attention-to-an-emerging-iatrogenic-phenomenon
#11
J L Modesto Dos Santos, P González Recio, O A Terry López, I Leturia Frade, B Aguiar Losada, J I Elejalde Guerra
Olmesartan is an angiotensin II type 1 receptor blocker commonly used in the treatment of hypertension. Several cases of sprue-like enteropathy associated with the use of this drug have been described which, even with important signs and limitations for the patient, present a full recovery after discontinuing the use of olmesartan. The case of a 64 year-old patient is presented, diagnosed with hypertension, under treatment with olmesartan-amlodipine, with chronic diarrhoea and villous atrophy on intestinal biopsies without diagnostic criteria for celiac disease and with complete remission after suspending discontinuing the use of olmesartan...
July 4, 2017: Anales del Sistema Sanitario de Navarra
https://www.readbyqxmd.com/read/28676194/chronic-diarrhea-and-deep-vein-thrombosis-during-treatment-with-olmesartan
#12
A Gião Antunes, A M Vaz, J Cadillá, B Peixe, H Guerreiro
No abstract text is available yet for this article.
July 1, 2017: Revista de Gastroenterología de México
https://www.readbyqxmd.com/read/28670240/telmisartan-induced-sprue-like-enteropathy-a-case-report-and-a-review-of-patients-using-non-olmesartan-angiotensin-receptor-blockers
#13
Harshal Surendra Mandavdhare, Vishal Sharma, Kaushal K Prasad, Amit Kumar, Manish Rathi, Surinder S Rana
Recent studies have identified sprue-like illness associated with the use of the antihypertensive agent olmesartan medoxomil. However, whether this condition is specific to the use of olmesartan or is associated with the use of drugs belonging to the class of "sartans" remains to be clarified. A 45-year-old woman with chronic kidney disease along with hypothyroidism and hypertension presented with chronic diarrhea and significant weight loss. Endoscopy of the upper gastrointestinal tract showed scalloping and grooving of the duodenum, and histopathological examination showed subtotal villous atrophy...
July 2017: Intestinal Research
https://www.readbyqxmd.com/read/28670083/olmesartan-associated-enteropathy
#14
Vivian S Ebrahim, Jason Martin, Stacey Murthy, Elizabeth Odstrcil, He Huang, Daniel Polter
Olmesartan, an angiotensin-receptor blocker frequently prescribed for hypertension, has been commercially available since 2002. In 2012, olmesartan-associated enteropathy was described, and the Food and Drug Administration now requires a black-box warning for olmesartan regarding severe diarrhea. The disorder can be life-threatening and often requires hospitalization. We present three cases that represent different aspects of this disorder, as well as some unusual features.
July 2017: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/28666209/the-role-of-ros-and-nf-%C3%AE%C2%BAb-pathway-in-olmesartan-induced-toxicity-in-hela-and-mcf-7-cell-lines
#15
Elham Bakhtiari, Azar Hosseini, Seyed Hadi Mousavi
We have recently shown that olmesartan could induce toxicity in HeLa and MCF-7 cell lines. In this study we investigated toxicity mechanism of olmesartan in HeLa and MCF-7 cell lines. HeLa and MCF-7 cells were cultured in DMEM in optimum conditions. Cells were pretreated with rutin as an antioxidant and treated with olmesartan as a cytotoxic agent. Cell proliferation was determined by MTT assay. The role of ROS was determined using DCFH-DA by flow cytometry analysis. Also, cells were treated with olmesartan (5mM) and Bay 11-7-82 (25μM) for 24h, then expression of apoptotic proteins including Bax, caspase3 and IκB were investigated in both cell lines by western blotting...
September 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28656296/the-ace2-ang%C3%A2-1-7-mas-receptor-axis-attenuates-cardiac-remodeling-and-fibrosis-in-post-myocardial-infarction
#16
Juan Wang, Wen He, Liping Guo, Yin Zhang, Hui Li, Suxia Han, Difei Shen
Myocardial remodeling serves an important role in the pathophysiology of coronary heart disease. The angiotensin-converting enzyme (ACE)2-angiotensin-(1-7) [Ang (1‑7)]‑Mas receptor (MasR) axis is a key regulator in myocardial remodeling and development of heart failure. To investigate how ACE2‑Ang‑(1‑7)‑MasR axis function on myocardial remodeling and cardiac fibrosis in post‑myocardial infarction (MI), male Sprague‑Dawley rats (weight, 200±20 g) were used to establish the model of myocardial infarction by ligating the left coronary artery...
August 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28625505/bioequivalence-study-of-a-new-fixed-dose-combination-tablet-containing-s-amlodipine-nicotinate-and-olmesartan-medoxomil-in-healthy-korean-male-subjects
#17
Mi Jin Oh, Hyun Hwan Hwang, Hyun Gyu Kim, Geun Hyeog Lee, Yun-Seok Cho, Sun Young Lee, Soo Yeon Kang, Kyung Hee Cho, Yun Young Lee, Yun Jeong Lee, Choon-Gon Jang, Seok-Yong Lee
PURPOSE: A fixed-dose combination (FDC) pill of amlodipine (relatively old calcium channel blocker as dihydropyridine) and olmesartan (relatively new angiotensin II receptor blocker) is used for hypertension that is not adequately controlled with a single-formulation drug. Because the FDC is a one-pill formulation, and amlodipine and olmesartan have different mechanisms of action, it is expected to improve patients' medication compliance and have an increased blood pressure-lowering efficacy...
July 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28608026/monotherapy-and-dual-combination-therapies-based-on-olmesartan-a-comprehensive-strategy-to-improve-blood-pressure-control
#18
REVIEW
Massimo Volpe, Caterina Santolamazza, Vittoria Mastromarino, Roberta Coluccia, Allegra Battistoni, Giuliano Tocci
Olmesartan medoxomil is an antihypertensive drug of the class of angiotensin II type 1 (AT1) receptor antagonists (or blockers), characterized by tight and prolonged binding to AT1 receptor compared to other molecules within the same class. These characteristics produce effective and sustained blood pressure reductions in hypertensive patients at different cardiovascular risk profile with a good tolerability profile. After a brief description of the pharmacological characteristics of olmesartan, we will provide a thorough overview of the clinical studies that investigated its efficacy and safety in the clinical management of hypertensive patients both in monotherapy and in dual combination therapies with either thiazide diuretics or calcium channel blockers...
June 12, 2017: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://www.readbyqxmd.com/read/28608025/triple-combination-therapies-based-on-olmesartan-a-personalized-therapeutic-approach-to-improve-blood-pressure-control
#19
REVIEW
Massimo Volpe, Caterina Santolamazza, Vittoria Mastromarino, Roberta Coluccia, Allegra Battistoni, Giuliano Tocci
Recent epidemiological surveys have demonstrated that effective and sustained blood pressure (BP) control is achieved in a relatively small proportion of treated hypertensive patients. Indeed, treatment of hypertension represents a key strategy for preventing coronary artery disease, stroke, congestive heart failure and cardiovascular death. Several interventions have been proposed by international guidelines for ameliorating hypertension management and control, mostly including integrated and multi-dimensional pharmacological and non-pharmacological strategies...
June 12, 2017: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://www.readbyqxmd.com/read/28583166/tardive-akathisia-related-to-the-anti-hypertensive-agent-sevikar-a-case-report
#20
Men-Ting Hsieh, Pao-Yen Lin, Chia-Jen Tsai, Chiung-Chih Chang, Yu Lee
BACKGROUND: Tardive akathisia (TA) is a subtype of tardive syndrome, and its etiology is still uncertain. Sevikar is an anti-hypertensive agent containing both amlodipine and olmesartan, and has never been reported to have an adverse reaction in patients with tardive syndrome. CASE PRESENTATION: A 57-year-old woman who took Sevikar for hypertension for 10 years developed TA one and a half years before receiving any psychiatric treatment. After switching from Sevikar to bisoprolol, she reported obvious improvement in her akathisia...
June 5, 2017: BMC Pharmacology & Toxicology
keyword
keyword
11664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"